LifeStance Health Group, Inc. (LFST) Stock Price & Analysis
LifeStance Health Group, Inc. (LFST) closed at USD 12.56 on Thursday, October 22, 2026, up 1.87% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 12.33; the Oct 22, 2026 session ranged USD 12.17–12.63 on volume of 4,162,969 shares. Market capitalization is $4.77B, with a 52-week range of USD 4.77–13.56 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LFST.md
Key facts (LFST)
- 1 of 80 tracked superinvestors hold LFST (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (11 analysts), mean target USD 14.4 (range 12–18).
- Total return with dividends: 1Y +144.4% vs S&P 500 +14.9%; 5Y +14.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.08, revenue estimate $432M.
Superinvestors (SEC 13F-HR, Q2 2026) (LFST)
1 of 80 tracked investors hold LFST. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.03% | $16.7M | Reduced -3.0% |
Analysts (LFST)
Consensus Buy (mean 2.00 on a 1–5 scale), 11 analysts; mean target USD 14.4 (low 12, high 18).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | Keybanc | Target raised | Overweight | $13 → $15 |
| 2026-09-10 | Barclays | Target raised | Overweight | $13 → $15 |
| 2026-09-09 | Canaccord Genuity | Target raised | Buy | $13 → $15 |
| 2026-08-19 | BTIG | Target raised | Buy | $16 → $18 |
| 2026-08-14 | JP Morgan | Target raised | Neutral | $9 → $13 |
| 2026-08-07 | BTIG | Target raised | Buy | $15 → $16 |
| 2026-07-24 | BTIG | Target raised | Buy | $12 → $15 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $11 → $13 |
| 2026-07-14 | Barclays | Target raised | Overweight | $9 → $13 |
| 2026-07-13 | Keybanc | Target raised | Overweight | $11 → $13 |
Total return (dividends reinvested) (LFST)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +144.4% | +14.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +145.1% | +2.8% |
| Volatility (annualized) | 50.1% | 59.9% |
| Max drawdown | -17.1% (May 2026→Jun 2026) | -71.7% (Nov 2021→Jul 2025) |
LFST analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.08 | $0.07 | +14.0% | $431.6M | 5 |
| Next quarter (ends Dec 2026) | $0.09 | $0.08 | +4.6% | $438.6M | 5 |
| Current fiscal year (ends Dec 2026) | $0.36 | $0.31 | +15.4% | $1.71B | 5 |
| Next fiscal year (ends Dec 2027) | $0.43 | $0.39 | +9.9% | $1.96B | 5 |
Key Statistics (as of October 23, 2026 at 09:25 UTC)
| Price | USD 12.56 |
|---|---|
| Change | ▲ 1.87% (up) |
| Previous Close | USD 12.33 |
| Open | USD 12.3 |
| Day Range | USD 12.17 – 12.63 |
| 52-Week Range | USD 4.77 – 13.56 |
| Volume | 4,162,969 shares |
| Market Cap | $4.77B |
| Exchange | NMS |
Technical Analysis (LFST)
Nexqual's technical model rates LFST "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:25 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.88 (neutral) |
| vs SMA50 | Above (USD 12.39) |
| MACD | 0.01 (positive) |
Analyst Ratings (LFST)
Wall Street analysts rate LFST "Buy" based on 11 analysts, with a mean price target of USD 14.4 (range USD 12–18), per Nexqual as of October 23, 2026 at 09:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 14.4 |
| High Target | USD 18 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (LFST)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.08 |
| Revenue Estimate | $431.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.11 vs est 0.08 ▲ beat |
| 2026-03-31 | USD 0.07 vs est 0.06 ▲ beat |
| 2025-12-31 | USD 0.09 vs est 0.05 ▲ beat |
| 2025-09-30 | USD 0.01 vs est 0.04 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financials & Fundamentals (LFST)
| Total Revenue | $1.58B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +26.10% |
| Gross Margin | +33.56% |
| Operating Margin | +7.25% |
| Profit Margin | +3.19% |
| ROE | +3.43% |
| Debt / Equity | 0.32 |
| Current Ratio | 1.38 |
| Total Cash | $225.94M |
| Total Debt | $474.15M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | $110.03M (7.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financial Health Score (LFST)
Nexqual rates LifeStance Health Group, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:25 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 34%, operating 7% (last 12 months) |
| Balance Sheet | Solid — $226M cash vs $474M debt |
| Cash Flow | Solid — FCF $110M (FY ended Dec 2025, 10-K), 8% margin |
| Efficiency | Weak — ROE 3%, ROA 2.3% |
Ownership (LFST)
| Insider Ownership | +3.07% |
|---|---|
| Institutional Ownership | +91.36% |
| Shares Outstanding | 380.15M |
| Float | 266.93M |
| Short % of Float | +8.49% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Leadership (LFST)
LifeStance Health Group, Inc. is led by David Patrick Bourdon, CEO & Director, per Nexqual as of October 23, 2026 at 09:25 UTC.
| CEO & Director | David Patrick Bourdon |
|---|---|
| Executive Chairman | Kenneth Alan Burdick |
| CFO & Treasurer | Ryan Bruce McGroarty |
| Chief Technology Officer | Vukasin Paunovich |
| Chief Operating Officer & Principal Operating Officer | Lisa Keise Miller |
Major Backers & Investors (LFST)
Notable institutional backers of LifeStance Health Group, Inc. include TPG GP A, LLC, FMR, LLC, Summit Partners, L.P., according to Nexqual as of October 23, 2026 at 09:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TPG GP A, LLC | 29.24% |
| FMR, LLC | 15.24% |
| Summit Partners, L.P. | 6.1% |
| Fidelity | 5.63% |
| Jennison Associates LLC | 3.16% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.51% |
| Vanguard Group | 6.2% |
| Dimensional Fund Advisors | 2.99% |
| State Street | 2.15% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OPCH | Option Care Health, Inc. | USD 31.29 | ▼ 0% |
| CON | Concentra Group Holdings Parent | USD 39.97 | ▲ 2.25% |
| NHC | National HealthCare Corporation | USD 243.07 | ▲ 3.17% |
| CHE | Chemed Corp | USD 520.15 | ▲ 1.72% |
| PACS | PACS Group, Inc. | USD 47.5 | ▲ 1.58% |
| ACHC | Acadia Healthcare Company, Inc. | USD 31.88 | ▲ 1.43% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt